N-(4-乙基苯基)-beta-丙氨酸 | 263896-26-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-(4-乙基苯基)-beta-丙氨酸
• 英文名称: 3-(4-ethylphenylamino)propionic acid
• 英文别名: 3-(4-Ethylanilino)propanoic acid
• CAS: 263896-26-0
• 化学式: C₁₁H₁₅NO₂
• 分子量: 193.246
• InChiKey: JWCHSITTXXCDJV-UHFFFAOYSA-N

物化性质

• 沸点：
  381.3±35.0 °C(Predicted)
• 密度：
  1.141±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-(4-乙基苯基)-beta-丙氨酸 在 磷酸酐 、 PPA 、 一氯化碘 作用下， 以 盐酸 为溶剂， 反应 2.17h， 生成 6-ethyl-8-iodo-2,3-dihydro-1H-quinolin-4-one
  参考文献：
  名称：

  Nanomolar Inhibitors of Staphylococcus aureus Methionyl tRNA Synthetase with Potent Antibacterial Activity against Gram-Positive Pathogens

  摘要：

  Potent nanomolar inhibitors of Staphylococcus aureus methionyl tRNA synthetase have been derived from a file compound high throughput screening hit. Optimized compounds show excellent antibacterial activity against staphylococcal and enterococcal pathogens, including strains resistant to clinical antibiotics. Compound II demonstrated in vivo efficacy in an S. aureus rat abscess infection model.

  DOI：

  10.1021/jm025502x
• 作为产物：
  描述：

  β-丙内酯 、 4-乙基苯胺 以 乙腈 为溶剂， 反应 4.0h， 以59%的产率得到N-(4-乙基苯基)-beta-丙氨酸
  参考文献：
  名称：

  Nanomolar Inhibitors of Staphylococcus aureus Methionyl tRNA Synthetase with Potent Antibacterial Activity against Gram-Positive Pathogens

  摘要：

  Potent nanomolar inhibitors of Staphylococcus aureus methionyl tRNA synthetase have been derived from a file compound high throughput screening hit. Optimized compounds show excellent antibacterial activity against staphylococcal and enterococcal pathogens, including strains resistant to clinical antibiotics. Compound II demonstrated in vivo efficacy in an S. aureus rat abscess infection model.

  DOI：

  10.1021/jm025502x

文献信息

• ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS
  申请人：Pinto Donald J.P.

  公开号：US20100016316A1

  公开（公告）日：2010-01-21

  The present invention provides compounds of Formula (I) or (II): or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L 1 , R 3 , R 4 , R 8a , R 11 and M are as defined herein. The compounds of Formula (I) or (II) are selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

  本发明提供了化合物的结构式（I）或（II）： 或其立体异构体、互变异构体、药学上可接受的盐或溶剂形式，其中变量A、L1、R3、R4、R8a、R11和M如本文所定义。结构式（I）或（II）的化合物是凝血级联和/或接触激活系统的丝氨酸蛋白酶酶的选择性抑制剂；例如凝血酶、Xa因子、XIa因子、IXa因子、VIIa因子和/或血浆激肽。具体而言，涉及选择性XIa因子抑制剂或fXIa和血浆激肽的双重抑制剂的化合物。本发明还涉及包含这些化合物的药物组合物以及使用它们治疗血栓栓塞和/或炎症性疾病的方法。
• WRINKLE-IMPROVING AGENT
  申请人：Shiseido Company, Limited

  公开号：EP1941861A1

  公开（公告）日：2008-07-09

  The invention provides a novel wrinkle-improving agent that has an effect of improving wrinkles, that does not entail problems of safety or pain even when applied to the skin, and that contains a very safe substance as an active component. A discovery was made that N-benzoyl-β-alanine, other specific β-alanine derivatives, and salts thereof have a wrinkle-improving effect, whereby a wrinkle-improving agent containing as an active component one, two, or more types of compounds selected from the group composed of these specific β-alanine derivatives and the salts thereof was developed.

  该发明提供了一种新型的改善皱纹的剂，具有改善皱纹的效果，即使应用于皮肤也不会带来安全或疼痛问题，并且包含一种非常安全的物质作为活性成分。发现N-苯甲酰-β-丙氨酸、其他特定的β-丙氨酸衍生物及其盐具有改善皱纹的效果，因此开发了一种改善皱纹的剂，其活性成分包含从这些特定的β-丙氨酸衍生物及其盐组成的群体中选择的一种、两种或更多种化合物。
• Synthesis and Heterocyclization of 1-Aryl-2-methyl-4-oxo-1,4,5,6-tetrahydropyridine-3-carboxylates
  作者：Birutė Sapijanskaitė、Kristina Mickevičienė、Kristina Kantminienė、Sergey Belyakov、Vytautas Mickevičius

  DOI：10.1002/jhet.2857

  日期：2017.9

  were synthesized by the reaction of corresponding ethyl 1‐substituted aryl‐2‐methyl‐4‐oxo‐1,4,5,6‐tetrahydropyridine‐3‐carboxylates with different hydrazines and hydroxylamine. Reaction of tetrahydropyridone with N,N‐dimethylformamide dimethyl acetal provided 1‐(5‐chloro‐2‐methylphenyl)‐2‐[2‐(dimethylamino)ethenyl]‐4‐oxo‐1,4,5,6‐tetrahydropyridine‐3‐carboxylate, which was cyclized into a bicyclic compound

  通过相应的乙基1取代的芳基-2-甲基-4-氧-1、4,5,6-四氢吡啶-3-羧酸酯与不同的肼和羟胺反应合成了一系列新型的异恶唑，二氢吡唑啉酮和四氢吡啶衍生物。四氢吡啶酮与N，N-二甲基甲酰胺二甲基乙缩醛的反应提供了1-（5-氯-2-甲基苯基）-2- [2-（二甲基氨基）乙烯基] -4-氧--1,4,5,6-四氢吡啶-3 -羧酸盐，经乙酸铵处理后被环化成双环化合物。通过IR，1 H NMR和13 C NMR光谱数据确认了所有合成化合物的结构。5-（5-氯-2-甲基苯基）-4-甲基-2-苯基-2,5,6,7-四氢-3 H的结构通过X射线分析数据明确分配了pyrazolo [4,3-c] pyridin-3-one。
• THIOPHENE DERIVATIVES AS FACTOR XIA INHIBITORS
  申请人：Han Wei

  公开号：US20090253766A1

  公开（公告）日：2009-10-08

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein the variables A, L 1 , R 3 , and R 11 are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

  本发明提供了式（I）的化合物：或其立体异构体、互变异构体、药学上可接受的盐、溶剂化物或前药，其中变量A、L1、R3和R11如本文所定义。式（I）的化合物可用作凝血级联和/或接触激活系统的丝氨酸蛋白酶酶的选择性抑制剂，例如凝血酶、Xa因子、XIa因子、IXa因子、VIIa因子和/或血浆卡利肌酶。特别地，涉及到选择性XIa因子抑制剂的化合物。本发明还涉及包含这些化合物的制药组合物以及使用它们治疗血栓栓塞和/或炎症性疾病的方法。
• [EN] QUINOLONES AS T-RNA SYNTHETASE INHIBITORS AND ANTIBACTERIAL AGENTS<br/>[FR] QUINOLONES TENANT LIEU D'INHIBITEURS D'ARNT SYNTHETASE ET D'AGENTS ANTIBACTERIENS
  申请人：SMITHKLINE BEECHAM PLC

  公开号：WO2000021949A1

  公开（公告）日：2000-04-20

  Compounds of formula (I), in which: R1 is aryl or heteroaryl; R2 is hydrogen, C¿(1-6)?alkyl, arylC(1-4)alkyl, arylC(2-4)alkenyl or C(1-6)alkylcarbonyl; R?3¿ is selected from halo, cyano, hydroxy, (C¿1-6)?alkyl (optionally substituted by halo, hydroxy, amino, carboxy or (C1-6)alkoxycarbonyl), (C3-7)cycloalkyl, C(1-6)alkoxy, amino, mono- or di-(C1-6)alkylamino, acylamino, carboxy, (C1-6)alkoxycarbonyl, carboxy(C1-6)alkyloxy, (C1-6)alkylthio, (C1-6)alkylsulphinyl, (C1-6)alkylsulphonyl, sulphamoyl, mono- and di-(C1-6)alkylsulphonyl, carbamoyl, mono- and di-(C1-6)alkylcarbamoyl, and heterocyclyl; m is 0 or an integer from 1 to 3; R?4¿ and a substituent on R1 are linked to form a saturated bridge comprising one or two carbon atoms and a heteroatom selected from O and NR5; R5 is hydrogen or C¿(1-6)?alkyl; Y is a linker group having from 2 to 6 methylene groups in a straight chain and in which one or more alkylene groups may have one or more C(1-6) alkyl substituents and which substituents may be linked to form a C2 or C3 alkylene bridge; Z is NH or O; and salts thereof, preferably pharmaceutically acceptable salts; are inhibitors of Saureus methionyl tRNA synthetase and thereof of use in therapy as antibacterial agents.

  化合物的公式（I），其中：R1是芳基或杂环芳基；R2是氢，C（1-6）烷基，芳基C（1-4）烷基，芳基C（2-4）烯基或C（1-6）烷基羰基；R3是选自卤素，氰基，羟基，（C1-6）烷基（可选地被卤素，羟基，氨基，羧基或（C1-6）烷氧羰基取代），（C3-7）环烷基，C（1-6）烷氧基，氨基，单或双（C1-6）烷基氨基，酰胺基，羧基，（C1-6）烷氧羰基，羧基（C1-6）烷氧基，（C1-6）烷基硫醇，（C1-6）烷基亚磺酰基，（C1-6）烷基磺酰基，磺酰胺基，单和双（C1-6）烷基磺酰基，氨基甲酰基，单和双（C1-6）烷基氨基甲酰基和杂环基；m为0或1至3的整数；R4和R1上的取代基连接形成饱和桥，包括一个或两个碳原子和一个选自O和NR5的杂原子；R5是氢或C（1-6）烷基；Y是具有2至6个亚甲基基团的连接基，在其中一个或多个亚甲基基团中可能有一个或多个C（1-6）烷基取代基，并且这些取代基可能连接形成C2或C3烷基桥；Z是NH或O；及其盐，优选为药物可接受盐；是Saureus甲硫氨酰-tRNA合成酶的抑制剂，因此在治疗中作为抗菌剂使用。